Arena rockets on early data in crowded S1P1 field
This article was originally published in Scrip
Despite a slew of competitors developing more advanced agents, Arena Pharmaceuticals saw its stock price rocket 76.2% higher on 7 January to $5.85 per share based on Phase Ib results for APD334, an orally available small molecule agonist of the sphingosine 1-phosphate 1 (S1P1) receptor.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.